An oral vaccine against candidiasis generated by a yeast molecular display system

Pathogens and Disease

Volumn 69, Issue 3, 2013, Pages 262-268

  Shibasaki, Seiji ^a   Aoki, Wataru ^b   Nomura, Takashi ^c   Miyoshi, Ayuko ^a   Tafuku, Senji ^c   Sewaki, Tomomitsu ^c   Ueda, Mitsuyoshi ^b  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c Genolac BL Corporation   (Japan)

Author keywords

Candida albicans; Cell surface engineering; Eno1p; Saccharomyces cerevisiae

Indexed keywords

CANDIDA ALBICANS VACCINE; ENOLASE; ENOLASE 1 PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CELL SURVIVAL; CONTROLLED STUDY; DISPLAY SYSTEM; DRUG EFFICACY; FEMALE; FUNGUS IMMUNITY; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; SACCHAROMYCES CEREVISIAE; SURVIVAL RATE; VACCINATION; YEAST; YEAST CELL;

CANDIDA ALBICANS; CELL SURFACE ENGINEERING; ENO1P; SACCHAROMYCES CEREVISIAE;

ADMINISTRATION, ORAL; ANIMALS; CANDIDA ALBICANS; CANDIDIASIS; CELL SURFACE DISPLAY TECHNIQUES; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; FUNGAL PROTEINS; FUNGAL VACCINES; MICE; RECOMBINANT PROTEINS; TWO-HYBRID SYSTEM TECHNIQUES; VACCINATION;

EID: 84893785602     PISSN: None     EISSN: 2049632X     Source Type: Journal    
DOI: 10.1111/2049-632X.12068     Document Type: Article

References (22)

1. Adachi K, Kawana K, Yokoyama T et al. (2010) Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7. Vaccine 28: 2810-2817.
2. Aoki W, Kitahara N, Miura N, Morisaka H, Yamamoto Y, Kuroda K & Ueda M (2011) Comprehensive characterization of secreted aspartic proteases encoded by a virulence gene family in Candida albicans. J Biochem 150: 431-438.
3. Aoki W, Ueda T, Tatsukami Y, Kitahara N, Morisaka H, Kuroda K & Ueda M (2013) Time-course proteomic profile of Candida albicans during adaptation to a fetal serum. Pathog Dis 67: 67-75.
4. Benko I, Hernádi F, Megyeri A, Kiss A, Somogyi G, Tegyey Z, Kraicsovits F & Kovács P (1999) Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte-macrophage progenitor cells in vitro. J Antimicrob Chemother 43: 675-681.
5. Berner VK, Sura ME & Hunter KW Jr (2008) Conjugation of protein antigen to microparticulate beta-glucan from Saccharomyces cerevisiae: a new adjuvant for intradermal and oral immunizations. Appl Microbiol Biotechnol 80: 1053-1061.
6. Enache-Angoulvant A & Hennequin C (2005) Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41: 1559-1568.
7. Hanahan D (1983) Studies on transformation of Escherichia coli with plasmids. J Mol Biol 166: 557-580.
8. Hube B, Sanglard D, Odds FC, Hess D, Monod M, Schäfer W, Brown AJ & Gow NA (1997) Disruption of each of the secreted aspartyl proteinase genes SAP1, SAP2, and SAP3 of Candida albicans attenuates virulence. Infect Immun 65: 3529-3538.
9. Ito H, Fukuda Y, Murata K & Kimura A (1983) Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153: 163-168.
10. Kuroda K, Matsui K, Higuchi S, Kotaka A, Sahara H, Hata Y & Ueda M (2009) Enhancement of display efficiency in yeast display system by vector engineering and gene disruption. Appl Microbiol Biotechnol 82: 713-719.
11. Li W, Hu X, Zhang X, Ge Y, Zhao S, Hu Y & Ashman RB (2011) Immunisation with the glycolytic enzyme enolase confers effective protection against Candida albicans infection in mice. Vaccine 29: 5526-5533.
12. Montagnoli C, Sandini S, Bacci A, Romani L & La Valle R (2004) Immunogenicity and protective effect of recombinant enolase of Candida albicans in a murine model of systemic candidiasis. Med Mycol 42: 319-324.
13. Morschhäuser J (2002) The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587: 240-248.
14. Noble SM & Johnson AD (2007) Genetics of Candida albicans, a diploid human fungal pathogen. Annu Rev Genet 41: 193-211.
15. Nucci M & Marr KA (2005) Emerging fungal diseases. Clin Infect Dis 41: 521-526.
16. Pfaller MA & Diekema DJ (2007) Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20: 133-163.
17. Rodloff C, Koch D & Schaumann R (2011) Epidemiology and antifungal resistance in invasive candidiasis. Eur J Med Res 16: 187-195.
18. Rodríguez I, Chamorro R, Novoa B & Figueras A (2009) β-Glucan administration enhances disease resistance and some innate immune responses in zebrafish (Danio rerio). Fish Shellfish Immunol 27: 369-373.
19. Shibasaki S, Kawabata A, Ishii J, Yagi S, Kadonosono T, Kato M, Fukuda N, Kondo A & Ueda M (2007) Construction of a novel synergistic system for production and recovery of secreted recombinant proteins by the cell surface engineering. Appl Microbiol Biotechnol 75: 821-828.
20. Shibasaki S, Maeda H & Ueda M (2009) Molecular display technology using yeast - arming technology. Anal Sci 25: 41-49.
21. Tamaru Y, Ohtsuka M, Kato K, Manabe S, Kuroda K, Sanada M & Ueda M (2006) Application of the arming system for the expression of the 380R antigen from red sea bream iridovirus (RSIV) on the surface of yeast cells: a first step for the development of an oral vaccine. Biotechnol Prog 22: 949-953.
22. Xin H & Cutler JE (2011) Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis. Clin Vaccine Immunol 18: 1656-1667.